Ó³»­´«Ã½

Jorge Diego Martin-Rufino is a physician-scientist in hematology-oncology and a research scientist II in the Lander lab at the Ó³»­´«Ã½. He is also a pediatrics resident at Harvard Medical School and Boston Children’s Hospital (BCH), and will join Dana-Farber Cancer Institute/BCH for fellowship training in pediatric hematology-oncology. 

In his research, he is pioneering new approaches to transform stem cell transplantation and to uncover the fundamental regulatory wiring of the genome. His prior work has led to novel methods for making hundreds of direct genetic edits to blood stem cells from bone marrow, uncovering new treatment strategies for diseases such as leukemia and sickle cell disease. His goal is to change bone marrow transplantation as we know it by enabling stem cell transplants with minimal toxicity, expanding their use to diseases where current risk–benefit profiles make them untenable.

Martin-Rufino is a recipient of the 2025-26 Next Generation Award at the Ó³»­´«Ã½. He was also selected as a 2024 STAT Wunderkind and was named to the Forbes 30 Under 30 list in Science for 2025. He received the National End-of-Degree Award in Medicine, awarded to the top medical graduate nationwide in Spain, and has been inducted into the Royal Academy of Medicine of Salamanca (Spain).

Martin-Rufino earned his medical degree at Universidad de Salamanca and his Ph.D. in biological and biomedical sciences at Harvard University.